Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren’s syndrome; supplementation with dehydroepiandrosterone restores the concentrations.
Finasteride is a selective 5-reductase type 2 inhibitor that reduces plasma 5-dihydrotestosterone levels and shrinks the size of the prostate . It is a widely used therapeutic agent in the treatment of benign prostatic hyperplasia, it is used in androgen deprivation therapy to treat prostate cancer and it has been examined as a chemopreventive agent for hormonedependent prostate cancer.
Was originally thought to act as a competitive inhibitor with nanomolar affinity for 5-reductase type 2 . More recently, it was found that finasteride acts as a mechanism-based inactivator of this enzyme. Finasteride prevents conversion of testosterone to Dihydrotestosterone (DHT) by the type II and III isoenzymes, resulting in a decrease in serum DHT levels by about 65–70% and in prostate DHT levels by up to 85–90%. In addition to inhibiting 5α-reductase, finasteride has also been found to competitively inhibit 5β-reductase (AKR1D1)
Both AKR1D1 and 5-reductase type 1 play important roles in the hepatic clearance of steroid hormones, suggesting that high dose finasteride may have an adverse effect on hepatic steroid metabolism.
So at this point I just can’t either confirm,neither deny that Finasteride is linked till some extent to Sjogren’s.